{"nctId":"NCT00183196","briefTitle":"Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone","startDateStruct":{"date":"2003-01"},"conditions":["Alcohol Dependence"],"count":150,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Naltrexone"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Naltrexone plus Gabapentin"]},{"label":"3","type":"SHAM_COMPARATOR","interventionNames":["Other: Inactive Placebo"]}],"interventions":[{"name":"Naltrexone","otherNames":[]},{"name":"Naltrexone plus Gabapentin","otherNames":[]},{"name":"Inactive Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meet criteria for primary alcohol dependence including loss of control of drinking\n* No more than one previous inpatient medical detoxification\n* Consumes on average 5 standard drinks for men and 4 standard drinks for women\n* Able to maintain sobriety for 4 days (with or without detox medications).\n* Able to read and understand questionnaires and Informed Consent\n* Lives within 50 miles of the study site\n\nExclusion Criteria:\n\n* Currently meets DSM-IV criteria for any other psychoactive substance dependency disorder except nicotine dependence\n* Ever abused opiates\n* Any psychoactive substance abuse, except marijuana and nicotine within the last 30 days as evidenced by subject report, collateral report, or urine drug screen.\n* Meets DSM-IV criteria for current Axis I disorder of major depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress syndrome, bipolar affective disorder, dissociative disorder or eating disorder, schizophrenia, or any other psychotic disorder or organic mental disorder.\n* Has current suicidal or homicidal ideation\n* Need for maintenance or acute treatment with any psychoactive medication including antiseizure medications.\n* Current use of disulfiram.\n* Clinically significant medical problems, such as cardiovascular, renal, GI or endocrine problem that would impair participation or limit medication ingestion.\n* Hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at least 3.0 times normal at screening and/or after 5 days of abstinence.\n* Sexually active females of child bearing potential who are pregnant (by urine HCG), nursing or who are not using a reliable form of birth control.\n* Has current charges pending for a violent crime (not including DUI related offenses).\n* Does not have a stable living situation and a reliable source of collateral reporting.\n* Has taken an opiate antagonist drug in the last month.\n* Has taken gabapentin in the last month or has experienced adverse effects from it at any time in the past.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Relapse to Drinking","description":"Time to relapse drinking which is 5 standard drinks perday for males and 4 standard drinks per day for females. Subjects had a minimum of 4 days of abstinence prior to being entered into the protocol.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.9","spread":"6.5"},{"groupId":"OG001","value":"59.6","spread":"7.6"},{"groupId":"OG002","value":"57.3","spread":"6.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["somnolence","Dizziness","Blurred vision","Premature ejaculation"]}}}